Reducing Pseudomonas sputum density in bronchiectasis
- 5 January 2021
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 57 (1), 2003390
- https://doi.org/10.1183/13993003.03390-2020
Abstract
Decreased airway bacterial load may have impact on clinical outcomes in bronchiectasis. The iBEST study demonstrates that tobramycin inhalation powder reduces P. aeruginosa sputum density in a dose-dependent manner in patients with bronchiectasis. https://bit.ly/3miO9fYThis publication has 20 references indexed in Scilit:
- Pseudomonas aeruginosa and lung function decline in patients with bronchiectasisClinical Microbiology & Infection, 2021
- The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysisThe Lancet Respiratory Medicine, 2019
- Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trialsThe Lancet Respiratory Medicine, 2019
- The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasisEuropean Respiratory Journal, 2018
- RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasisEuropean Respiratory Journal, 2018
- RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasisEuropean Respiratory Journal, 2018
- European Respiratory Society guidelines for the management of adult bronchiectasisEuropean Respiratory Journal, 2017
- Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research CollaborationEuropean Respiratory Journal, 2016
- Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trialsThe Lancet Respiratory Medicine, 2014
- Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2014